{
    "clinical_study": {
        "@rank": "104336", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1: Rosuvastatin + BMS-919373", 
                "arm_group_type": "Experimental", 
                "description": "Rosuvastatin 10 mg tablet orally once for Day 1 and 5\nBMS-919373: 100 mg dose on Day 4 and 30 mg dose once daily on Days 5, 6 and 7 of Microcrystalline suspension"
            }, 
            {
                "arm_group_label": "Cohort 2: Atorvastatin + BMS-919373", 
                "arm_group_type": "Experimental", 
                "description": "Atorvastatin 40 mg tablet once for Days 1 and 5\nBMS-919373: 100 mg dose on Day 4 and 30 mg dose once daily on Days 5, 6 and 7 of Microcrystalline suspension"
            }
        ], 
        "brief_summary": {
            "textblock": "This purpose of this study is to assess the effects of BMS-919373 on the single dose\n      Pharmacokinetics (PK) of Rosuvastatin and Atorvastatin in healthy subjects."
        }, 
        "brief_title": "Drug Interaction Statin", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Coronary Syndromes", 
        "condition_browse": {
            "mesh_term": "Acute Coronary Syndrome"
        }, 
        "detailed_description": {
            "textblock": "Primary Purpose: Other - To assess the effects of BMS-919373 on the single dose PK of\n      Rosuvastatin and Atorvastatin in healthy subjects"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com.\n\n        Inclusion Criteria:\n\n          -  Signed Written Informed Consent form\n\n          -  Healthy subjects as determined by no clinically significant deviation from normal in\n             medical and surgical history, physical examination, physical measurements, vital\n             signs, 12-lead ECG, 24-hour telemetry, and clinical laboratory tests\n\n          -  Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive\n\n          -  Men and women, ages 18 to 55 yrs, inclusive\n\n        Exclusion Criteria:\n\n          -  Current or history of cardiovascular diseases, including arrhythmias, coronary heart\n             disease, and congestive heart failure\n\n          -  Current or history of symptomatic hypotension\n\n          -  Current or history of liver diseases, including cirrhosis and liver failure\n\n          -  Current or history of kidney diseases, including nephrotic syndrome, renal failure,\n             nephrolithiasis, and urolithiasis\n\n          -  Current or history of neurological diseases, including presyncope, syncope,\n             convulsive disorders such as epilepsy, cerebral thrombosis and cerebral embolism,\n             transient ischemic attack, and stroke; or mental disorders Exceptions for\n             presyncope/syncope related to vasovagal responses are allowable at the discretion of\n             the investigator\n\n          -  History of significant head injury in the last 2 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02089061", 
            "org_study_id": "CV205-029"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1: Rosuvastatin + BMS-919373", 
                    "Cohort 2: Atorvastatin + BMS-919373"
                ], 
                "intervention_name": "BMS-919373", 
                "intervention_type": "Drug", 
                "other_name": "IKur Inhibitor"
            }, 
            {
                "arm_group_label": "Cohort 1: Rosuvastatin + BMS-919373", 
                "intervention_name": "Rosuvastatin", 
                "intervention_type": "Drug", 
                "other_name": "Crestor\u00ae"
            }, 
            {
                "arm_group_label": "Cohort 2: Atorvastatin + BMS-919373", 
                "intervention_name": "Atorvastatin", 
                "intervention_type": "Drug", 
                "other_name": "Lipitor\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Atorvastatin", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 14, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Open-label, Single-sequence Study to Evaluate the Effect of Coadministration of BMS-919373 on the Single-dose Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum observed plasma concentration (Cmax) of Rosuvastatin and Atorvastatin", 
                "safety_issue": "No", 
                "time_frame": "28 timepoints up to day 10"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time zero to 72 hours (AUC(0-72)) of Rosuvastatin and Atorvastatin", 
                "safety_issue": "No", 
                "time_frame": "26 timepoints up to day 8"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of Rosuvastatin and Atorvastatin", 
                "safety_issue": "No", 
                "time_frame": "28 timepoints up to day 10"
            }, 
            {
                "measure": "Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of Rosuvastatin and Atorvastatin", 
                "safety_issue": "No", 
                "time_frame": "28 timepoints up to day 10"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02089061"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time of maximum observed plasma concentration (Tmax) of Rosuvastatin and Atorvastatin", 
                "safety_issue": "No", 
                "time_frame": "28 timepoints up to day 10"
            }, 
            {
                "measure": "Terminal plasma half life (T-HALF) of Rosuvastatin and Atorvastatin", 
                "safety_issue": "No", 
                "time_frame": "28 timepoints up to day 10"
            }, 
            {
                "measure": "Apparent total body clearance (CLT/F) of Rosuvastatin and Atorvastatin", 
                "safety_issue": "No", 
                "time_frame": "28 timepoints up to day 10"
            }, 
            {
                "description": "Adverse Event (AE)\nSerious Adverse Event (SAE)", 
                "measure": "Safety based on results of physical examinations, vital sign measurements, ECGs, 24-hour telemetry, clinical laboratory tests, and physical measurements and will also include the incidence of AEs, SAEs and AEs leading to discontinuation", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 10"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}